Back to Search
Start Over
Prognostic role of cyclin D2/D3 in multiple human malignant neoplasms: A systematic review and meta‐analysis
- Source :
- Cancer Medicine, Vol 8, Iss 6, Pp 2717-2729 (2019), Cancer Medicine
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Cyclin D2/D3 (CCND2/3) are core components of the machinery that drives cell cycle progression and therefore, are associated with tumorigenesis. Currently, there are contradictory evidences on the function of CCND2/3 in tumorigenesis. Thus, we conducted a comprehensive meta‐analysis to derive a precise predictive value of CCND2/3 in various tumors. We searched PubMed, EMBASE, Web of Science for eligible studies up to October 8, 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of OS or DFS/PFS/RFS were calculated using Forest plot analysis to demonstrate their associations. A total of 14 studies were ultimately included in this meta‐analysis. Our results indicated CCND2/3 played an oncogenic role in all of the cancer patients (CCND2: pooled HR = 2.21, 95% CI: 1.67‐2.93; CCND3: pooled HR = 2.29, 95% CI: 1.05‐5.03). In tumor subgroup, CCND2 was associated with shorter OS in patients with gastric cancer (HR = 2.20, 95% CI: 1.66‐2.92), whereas it might be a tumor suppressor in NSCLC (HR = 0.28, 95% CI: 0.12‐0.64). In addition, CCND3 was correlated to reduced OS in breast cancer patients (HR = 1.64, 95% CI: 1.07‐2.52) and shorter DFS/PFS/RFS in bladder cancer patients (HR = 4.60, 95% CI: 1.89‐12.57). Taken together, CCND2/3 could be the promising biomarkers for predicting the prognosis of patients with malignant neoplasms.
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Gene Expression
Kaplan-Meier Estimate
medicine.disease_cause
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Breast cancer
Cyclin D2
Neoplasms
Internal medicine
Databases, Genetic
Biomarkers, Tumor
medicine
Humans
Radiology, Nuclear Medicine and imaging
Cyclin D3
Original Research
Proportional Hazards Models
Bladder cancer
business.industry
Hazard ratio
Clinical Cancer Research
Cancer
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
030104 developmental biology
meta‐analysis
030220 oncology & carcinogenesis
Meta-analysis
Disease Susceptibility
prognosis
business
Carcinogenesis
Publication Bias
Subjects
Details
- ISSN :
- 20457634
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....be13f7d0ec5c4db47b449953bafb67ec